Trilinolein, a fat molecule derived from cannabis seeds, improved atopic dermatitis in mice by repairing mitochondrial dysfunction and restoring the skin barrier through the AhR-Nrf2 pathway.
Dermatology researchers; people with atopic dermatitis interested in cannabis-derived treatments.
Trilinolein performed comparably to prescription drug crisaborole in mouse eczema model
What the researchers found
Topically applied trilinolein improved DNCB-induced eczema-like lesions in mice, increased terminal differentiation proteins, decreased oxidative stress marker NOX2, restored mitochondrial morphology and membrane potential, and reduced mitochondrial DNA release in inflamed skin cells. These effects depended on the AhR signaling pathway.
Why it matters
Atopic dermatitis affects millions of people and current treatments often have significant side effects. Trilinolein from cannabis seeds targets a newly recognized disease mechanism -- mitochondrial dysfunction in skin cells -- and performed comparably to the prescription drug crisaborole in this preclinical model.
The numbers in context
Trilinolein increased expression of terminal differentiation proteins and decreased NOX2 expression, comparable to the positive control crisaborole. It reduced ROS fluorescence intensity, restored mitochondrial membrane potential, and decreased mtDNA release in stimulated keratinocytes. AhR, CYP1A1, and Nrf2 protein expression increased in a dose-dependent manner.
How the study worked
Combined approach using single-cell transcriptome analysis of chronic atopic dermatitis patients vs healthy controls, DNCB-induced eczema model in BALB/c mice, and IL-4/TNF-alpha-stimulated HaCaT keratinocytes. HPLC-ESI-MS/MS identified active compounds from Cannabis fructus. Proteomics explored mechanisms.
What this study cannot tell us
Preclinical study only. Mouse skin differs significantly from human skin. The DNCB-induced model does not fully replicate the complexity of human atopic dermatitis. Clinical trials in humans are needed to confirm efficacy and safety.
How to read the evidence
Preliminary: well-designed preclinical study with clear mechanistic evidence across multiple model systems, but not yet tested in humans.
When this study was published
2024 preclinical study.
The bigger picture
Cannabis seeds (Cannabis fructus) have been used in traditional medicine and cosmetics for centuries. Identifying trilinolein as an active compound with a clear molecular mechanism connects traditional use to modern pharmacology and opens a pathway for developing targeted dermatological treatments from cannabis-derived ingredients.
Questions still open
- Would trilinolein be effective in human atopic dermatitis patients? How does it compare to existing topical treatments in terms of long-term efficacy and side effects?
Common questions
What is trilinolein?
How does mitochondrial dysfunction relate to eczema?
Read the original research
Targeting mitochondrial dysfunction in atopic dermatitis with trilinolein: A triacylglycerol from the medicinal plant Cannabis fructus.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 132, 155856
Citation
Wang, Yi; Lu, Hanzhi; Cheng, Linyan; Guo, Wanjun; Hu, Yue; Du, Xinran; Liu, Xin; Xu, Mingyuan; Liu, Yeqiang; Zhang, Yanbin; Xi, Ruofan; Wang, Peiyao; Liu, Xin; Duan, Yanjuan; Zhu, Jianyong; Li, Fulun. (2024). Targeting mitochondrial dysfunction in atopic dermatitis with trilinolein: A triacylglycerol from the medicinal plant Cannabis fructus.. Phytomedicine : international journal of phytotherapy and phytopharmacology, 132, 155856. https://doi.org/10.1016/j.phymed.2024.155856